“Huntington’s Disease Market”
As per DelveInsight, the Huntington’s Disease Market is anticipated to grow immensely in the coming years owing to the launch of upcoming therapies, research and development and the increase in the incident population of Huntington’s Disease in the 7MM.
DelveInsight’s “Huntington’s Disease Market Insights, Epidemiology, and Market Forecast 2034” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Huntington’s Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Huntington’s Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Key highlights from the Huntington’s Disease Market Report:
-
The anticipated growth of the Huntington’s disease market will be driven by the emergence of innovative treatments, increasing disease prevalence, heightened research and development efforts, and advancements in genetic testing. The market is set to experience a surge due to the growing prevalence and awareness of the disease, alongside the impact of new, multi-stage pipeline products that will significantly alter the market landscape.
-
Key Huntington’s Disease Companies working in the market are Prilenia Therapeutics, Neurocrine Biosciences, SOM Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics, UniQure Biopharma, Wave life sciences, Takeda, Medesis Pharma, and others
-
Key Huntington’s Disease Therapies are Pridopidine, Tominersen, and others
-
The treatment for Huntington’s disease is complex as there exists no cure for Huntington’s disease, and there are no treatments known to slow or reverse its process. The current treatment available is symptoms specific, with the treatment goal to slow down the course of the disease and help affected people function for as long and as comfortably as possible.
-
As per DelveInsight’s estimates, the total prevalent cases of Huntington’s disease were more than 81,000 in seven major markets.
-
Currently, the treatment strategies include the usage of many medications to treat specific symptoms such as medicines for depression, mood swings, and involuntary/abnormal movements and behaviors. The US FDA has approved AUSTEDO (deutetrabenazine) and XENAZINE (tetrabenazine) for the treatment of chorea associated with Huntington’s disease.
-
In June 2024, PTC Therapeutics declared that it can resume a Phase 2 trial of its Huntington’s disease drug in the U.S., following the Food and Drug Administration’s review of data showing the pill reduced a mutant protein linked to the disorder.
-
In August 2023, the US FDA granted approval for INGREZZA (valbenazine) capsules to treat chorea associated with Huntington’s disease in adults. The US holds the largest share of the Huntington’s disease market, accounting for over 70% of the 7MM market, compared to the EU4 countries (Germany, Spain, Italy, France), the United Kingdom, and Japan.
-
From 2024 to 2034, the market for Huntington’s disease treatments is expected to expand due to the introduction of pipeline drugs like pridopidine and ANX005. These candidates aim to address significant unmet needs, particularly the lack of disease-modifying therapies.
Read detailed insights on Huntington’s Disease market outlook 2034 @ https://www.delveinsight.com/sample-request/huntingtons-disease-market
Huntington’s Disease Overview
Huntington’s disease is inherited in an autosomal dominant pattern, meaning that having just one copy of the mutated gene (inherited from either parent) is enough for the disease to manifest, overshadowing the normal gene. This condition is caused by mutations in the huntingtin gene located on the short arm of chromosome 4 (4p16.3).
Diagnosing Huntington’s disease involves a comprehensive physical examination, a review of the patient’s family medical history, neurological and psychiatric assessments, and genetic testing.
The Huntington’s disease report outlines the disease’s pathophysiology, diagnostic methods, and a detailed treatment approach. It also includes a real-world case study, tracing a patient’s journey from the onset of symptoms through diagnosis and the entire treatment process.
Huntington’s Disease Treatment Market
Current treatment strategies involve various medications aimed at managing specific symptoms. For example, Deutetrabenazine (AUSTEDO), tetrabenazine (XENAZINE), and valbenazine (INGREZZA) are FDA-approved for treating chorea associated with Huntington’s disease.
In addition, dopamine blockers and medications like amantadine can help manage involuntary movements and some abnormal behaviors. To address emotional and behavioral issues, antidepressants and antipsychotics are commonly prescribed. Selective serotonin reuptake inhibitors (SSRIs), such as Lexapro, Prozac, and Zoloft, are frequently used to treat depression in Huntington’s disease patients.
Huntington’s Disease Epidemiology Assessment
The epidemiology section offers a comprehensive overview of the historical, current, and projected epidemiological patterns in the seven major markets (7MM) between 2020 and 2034. It aids in understanding the factors contributing to present and anticipated epidemiological trends through the examination of various studies and research findings. Additionally, the section includes an in-depth analysis of the diagnosed and prevalent patient populations, emerging trends, and the perspectives of leading experts in the field.
Huntington’s Disease Epidemiology Insights:
-
The findings indicate that Huntington’s disease is more prevalent among the elderly population (≥60 years).
-
In the 7MM, over 21,000 cases were reported in individuals over 60 years old. According to DelveInsight’s estimates, the United States accounted for more than 50% of the total diagnosed cases of Huntington’s disease within the 7MM in 2023.
-
Among the EU4 countries and the UK, Germany had the highest number of Huntington’s disease cases in 2023.
-
DelveInsight’s consultant estimates that Stage II cases comprised the majority of Huntington’s disease cases in the 7MM in 2023.
Huntington’s Disease Marketed Drugs
Huntington’s Disease Emerging Drugs
Learn How the Huntington’s Disease Market Will Evolve and Grow by 2034 @ https://www.delveinsight.com/sample-request/huntingtons-disease-market
Huntington’s Disease Treatment Market
Key Huntington’s Disease companies, including Prilenia Therapeutics, Annexon Biosciences, and others, are advancing their lead candidates through various stages of clinical development to explore their potential for treating Huntington’s disease.
The United States accounts for over 70% of the Huntington’s disease market, exceeding the combined market size of Germany, Spain, Italy, France (collectively known as EU4), the United Kingdom, and Japan.
Leading Players in the Huntington’s Disease Therapeutics Market Include:
Huntington’s Disease Companies working in the market are MicuRx, Basilea pharmaceuticals, AbbVie, Cubist Pharms LLC, Nabriva Therapeutics, Melinta Therapeutics, Durata Therapeutics, and others.
Huntington’s Disease Report Covers the In-depth Assessment of the Emerging Huntington’s Disease Drugs & Key Companies. Download the Huntington’s Disease Market Sample Report to Learn More @ https://www.delveinsight.com/report-store/huntingtons-disease-market
Table of Contents
1. Key Insights
2. Executive Summary
3. Huntington’s Disease Competitive Intelligence Analysis
4. Huntington’s Disease Market Overview at a Glance
5. Huntington’s Disease Disease Background and Overview
6. Huntington’s Disease Patient Journey
7. Huntington’s Disease Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Huntington’s Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Huntington’s Disease Unmet Needs
10. Key Endpoints of Huntington’s Disease Treatment
11. Huntington’s Disease Marketed Products
12. Huntington’s Disease Emerging Drugs and Latest Therapeutic Advances
13. Huntington’s Disease Seven Major Market Analysis
14. Attribute Analysis
15. Huntington’s Disease Market Outlook (In US, EU5, and Japan)
16. Huntington’s Disease Access and Reimbursement Overview
17. KOL Views on the Huntington’s Disease Market
18. Huntington’s Disease Market Drivers
19. Huntington’s Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Trending Reports by DelveInsight:
Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Huntington\’s Disease Market Forecast 2034: Therapies, Clinical trials, prevalence, Treatment Algorithms by DelveInsight | MicuRx, Basilea pharmaceuticals, AbbVie, Cubist Pharms LLC, Nabriva Therapeuti
